Cas:781-35-1 1,1-Diphenylacetone manufacturer & supplier

Chemical Name:1,1-Diphenylacetone

CAS.NO:781-35-1

Synonyms:1,1-diphenyl-2-propanon;EINECS 212-307-9;1,1-Diphenylacetone;UNSYM-DIPHENYLACETONE;1,1-Diphenylactone;2-Propanone, 1,1-diphenyl-;1,1-diphenyl acetone;2-OXO-1,1-DIPHENYLPROPANE;methyldiphenyl acetate;Diphenyl Acetone;BENZHYDRYL METHYL KETONE;1,1-diphenyl-2-propanone;1,1-DIPHENYLPROPAN-2-ONE;MFCD00008759

Molecular Formula:C₁₅H₁₄O

Molecular Weight:210.271

HS Code:2914399090

Physical and Chemical Properties:

Melting point:59-63 °C(lit.)

Boiling point:307.6±11.0 °C at 760 mmHg

Density:1.1±0.1 g/cm3

Index of Refraction:1.563

PSA:17.07000

Exact Mass:210.104462

LogP:2.99

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like 1,1-diphenyl-2-propanon chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00008759 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,1-diphenyl-2-propanone Use and application,1,1-Diphenylactone technical grade,usp/ep/jp grade.

Related News: ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy. 1,1-Diphenylacetone manufacturer ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy. 1,1-Diphenylacetone supplier With the structural upgrade of the pharmaceutical industry in developed countries, the transfer of related industrial chains has taken place globally, and it has also had a profound impact on Chinese pharmaceutical companies. near 1,1-Diphenylacetone vendor Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study. 1,1-Diphenylacetone factory RELATED: CVS, Walgreens begin rolling out over-the-counter COVID tests from Abbott, Ellume and more